Search the Newsreel

Dynatrace (DT) Shares Moved, What Is Driving Attention Now?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Dynatrace (DT) is in focus after a series of August updates that combine earnings, fresh guidance, a completed buyback and leadership changes around …

DT Stock Gains Over 4% — Dynatrace Draws Wall Street PT Hikes As AI Demand Fuels Bullish Calls

OrthoPediatrics Sees ‘Inflection Point’ as New Products Fuel Record Quarter

OrthoPediatrics reported record revenue and adjusted EBITDA in Q2, with CEO Dave Bailey highlighting new "super cycle" products and summer volumes as key drivers. The company anticipates continued growth in the second half of the year, driven by increasing contributions from new hip and …

PATRIOT NATIONAL BANCORP INC Q2 2026: Revenue $16.42M, Net income $0.14M, EPS $0— 10-Q Summary

PATRIOT NATIONAL BANCORP INC (PNBK) reported improved second-quarter 2026 results, showing increased revenue and a return to net income compared to a loss in the previous year. This positive shift was primarily driven by substantial loan growth and stronger yields from securities. The company …

AtriCure (ATRC) Is Up 10.1% After Unveiling 2030 Revenue Goal And Trial-Driven Expansion Plans

AtriCure (ATRC) saw a 10.1% stock increase after announcing a goal of US$1.00 billion in revenue by 2030, driven by its atrial fibrillation, left atrial appendage management, and postsurgical pain-management franchises, alongside new product launches. The company's expansion plans heavily rely on the successful …

DA Davidson reiterates Dynatrace stock Buy rating on Arize deal

DA Davidson has reiterated its Buy rating and a $65.00 price target for Dynatrace Inc. (NYSE:DT) following the company's acquisition of Arize for $915 million, a move expected to accelerate Dynatrace's expansion into AI Observability and boost ARR growth. This strategic acquisition, supported by …

Patriot National Bancorp, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Dynatrace Falls as Investors Weigh $915 Million Arize Deal

Dynatrace (DT) shares fell 3.3% after investors reacted to its planned $915 million acquisition of AI observability company Arize. While the deal is intended to boost ARR growth, concerns arose over the significant purchase price, cash-and-stock structure, and management's statement that it would dilute …

Atrium Therapeutics (RNA): RA Capital and affiliates report 0% beneficial ownership

RA Capital Management, L.P., and its affiliates, including Peter Kolchinsky and Rajeev Shah, have filed an amended Schedule 13G/A, reporting 0% beneficial ownership of Atrium Therapeutics (RNA) common stock as of June 30, 2026. This indicates they hold no shares and possess no voting …

Starboard adds Dynatrace, Flowserve, and exits Beckton Dickson, among top Q2 trades

takasuu/iStock via Getty Images Starboard Value added Dynatrace (DT [https://seekingalpha.com/symbol/DT]) and Flowserve (FLS [https://seekingalpha.com/symbol/FLS]), while the fund exited Beckton Dickinson (BDX [https://seekingalpha.com/symbol/BDX]) and Gen Digital (GEN [https://seekingalpha.com/symbol/GEN]), according to its latest 13F filing. The activist fund led by Jeff Smith added 8.9M Dynatrace (DT …

Sessa Capital discloses 8.8% Atrium Therapeutics (RNA) ownership through managed funds

Sessa Capital IM, L.P. and John Petry have reported a beneficial ownership of 1,500,000 shares of Atrium Therapeutics, Inc. common stock, which accounts for 8.8% of the outstanding shares. This disclosure was made via a SCHEDULE 13G SEC filing, indicating a passive investment. The …

Dynatrace (NYSE:DT) Given New $60.00 Price Target at Truist Financial

Truist Financial has increased its price target for Dynatrace (NYSE:DT) to $60.00 from $55.00, maintaining a "buy" rating, which suggests a 20.65% upside. The company recently surpassed quarterly earnings expectations, reporting adjusted EPS of $0.48 against an anticipated $0.45, and revenue of $554.55 million, …

Viatris Inc. stock rises Friday, outperforms market

Viatris Inc. (VTRS) stock increased by 1.18% to $16.23 on Friday, despite a general market downturn where the S&P 500 Index and Dow Jones Industrial Average both saw declines. This gain ended a two-day losing streak for Viatris, indicating a resilient performance against broader …

Dynatrace's Arize Acquisition Seen to Accelerate Organic Growth, RBC Capital Markets Says

RBC Capital Markets believes that Dynatrace's acquisition of Arize AI, Inc. will accelerate the company's organic growth. Dynatrace has signed a definitive agreement to acquire Arize AI for approximately $920 million in a deal involving cash and stock. This news comes alongside several analyst …

PAX|Patria Investments Ltd|Price:11.545|Chg%:-0.085

Patrick Industries (PATK) Looks Undervalued On Paper, Is The Market Missing Its Fair Value?

Patrick Industries (PATK) is currently considered undervalued with a fair value of $109.80 against a last close of $86.46, despite a 22% year-to-date share price decline. The company's longer-term performance and innovation in products like composite roofing systems and marine tower systems support a …

T. Rowe Price Associates (RNA) discloses 8.6% Atrium Therapeutics ownership in 13G/A

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 1,472,984 shares in Atrium Therapeutics Inc., which constitutes an 8.6% stake in the company. The filing indicates that T. Rowe Price Associates holds sole voting power over 1,472,772 …

Patrick Industries declares $0.47 quarterly dividend

Patrick Industries Inc. (NASDAQ:PATK) announced a quarterly cash dividend of $0.47 per share, payable on September 8, 2026, to shareholders of record as of August 24, 2026. The company is a key component solutions provider for the recreational vehicle, marine, powersports, and housing markets, …

NYLI CBRE Global Infrastructure Megatrends Term Fund (NYSE: MEGI) Declares Availability of Section 19(a) Notice for August 2026

Q3 Earnings Estimate for AptarGroup Issued By Zacks Research

Patrick Industries Sets Aug. 24 Record Date for $0.47 Dividend

Latrobe Magnesium (ASX:LMG)Locks In Up To $16 Million To Chase First Magnesium Metal

Gayatri Highways reports consolidated net loss of Rs 2.83 crore in the June 2026 quarter

Atrium Therapeutics, Inc. (RNA) Stock Price, News, Quote & History

Atrium Therapeutics, Inc. (RNA), formerly Prosensa Holding B.V. Ordinary Shares, is a biopharmaceutical company focused on developing RNA therapeutics for cardiomyopathies. The company's stock is currently trading at $12.84, with a slight increase after hours. Analysts maintain a "Buy" rating with a target price …

5 Insightful Analyst Questions From Dynatrace’s Q2 Earnings Call

5 Insightful Analyst Questions From Dynatrace's Q2 Earnings Call Dynatrace's second quarter was marked by strong revenue growth and a positive market response, as the company surpassed Wall Street's revenue expectations and posted robust demand for its cloud observability platform. Management attributed this momentum …

Avidity Biosciences (NASDAQ:RNA) Issues Earnings Results

Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?

According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded …

Atrium Therapeutics (RNA) grows collaboration revenue to $22.6M while scaling R&D spend

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," …

Atrium Therapeutics, Inc. Q2 2026: Revenue $3M, EPS $(1.18) — 10-Q Summary

Atrium Therapeutics, Inc. reported its Q2 2026 results, with revenue declining to $3M from $3.85M in the prior year, and a diluted loss per share of $(1.18), worse than $(0.75) year-over-year. Despite the financial decline, the company highlighted an increase in collaboration revenue, clinical …

Form 8K Atrium Therapeutics Inc For: 13 August By Investing.com

This article from Investing.com is a brief announcement regarding an 8K filing by Atrium Therapeutics Inc. for August 13th. The content is very minimal, essentially serving as a headline to notify readers of the regulatory filing, without providing any further details about the filing …

Patrick Industries (PATK): Wellington Group reports 1.62M-share, 4.94% passive stake

Wellington Management Group LLP, along with its affiliates, has reported an amended passive ownership of 1,623,974 shares, or 4.94%, of Patrick Industries (PATK) common stock as of June 30, 2026. The filing, a Schedule 13G/A, indicates that the shares are beneficially owned by clients …

Viatris (VTRS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, August 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS CEO - Scott SmithInterim CFO - Paul CampbellChief R&D Officer - Philippe MartinChief Commercial Officer - Corinne Le GoffHead of Capital Markets - Bill Szablewski TAKEAWAYS Revenue -- …